Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting
Launched by CHIESI SA/NV · Aug 8, 2018
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This non-interventional study assesses the real-life effectiveness and safety of the fixed triple therapy Trimbow® compared to free triple therapy, considering patient individual data, in clinical practice at second and thirdline centres in patients with confirmed moderate to severe chronic obstructive pulmonary disease.
This is an hypothesis generating study. No formal primary endpoint is defined; parameters are evaluated in an exploratory or descriptive manner.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has provided written informed consent
- • Patient is aged 40 years or older at time of initiation of Trimbow® treatment
- • Patient is diagnosed with moderate or severe chronic obstructive pulmonary disease confirmed by spirometry (post-bronchodilation) based on the Global Initiative for chronic obstructive lung disease (GOLD) 2018 classification
- • Patient treated with double inhalation or free triple therapy (using at least 2 devices) who are prescribed Trimbow®
- Exclusion Criteria:
- • Hypersensitivity to the active substances or to any of the excipients listed below:
- • Ethanol anhydrous
- • Hydrochloric acid
- • Norflurane (propellant)
About Chiesi Sa/Nv
Chiesi SA/NV is a global pharmaceutical company headquartered in Parma, Italy, specializing in the research, development, and commercialization of innovative therapeutic solutions. With a strong commitment to improving patient outcomes, Chiesi focuses on areas such as respiratory diseases, rare diseases, and maternal and pediatric health. The company is dedicated to advancing scientific knowledge through robust clinical trials and collaborations, ensuring the highest standards of safety and efficacy in its products. Chiesi's passion for sustainability and social responsibility further underscores its mission to create a healthier future for communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Brussel, , Belgium
Charleroi, , Belgium
Mechelen, , Belgium
Antwerp, , Belgium
Roeselare, , Belgium
Liège, , Belgium
Gent, Oost Vlaanderen, Belgium
Kortrijk, West Vlaanderen, Belgium
Antwerp, , Belgium
Antwerp, , Belgium
Charleroi, , Belgium
Montigny Le Tilleul, , Belgium
Namur, , Belgium
Tournai, , Belgium
Patients applied
Trial Officials
Guy Brusselle, MD-PhD
Principal Investigator
University Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials